MYRIAD GENETICS INC

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the and (unaudited)

Condensed Consolidated Statements of Operations (unaudited)

(in millions, except per share amounts)

	Three months endedJune 30,		Six months endedJune 30,
	2025	2024	2025	2024
Revenue	$213.1	$211.5	$409.0	$413.7
Cost of revenue	61.3	64.4	123.0	128.9
Gross profit	151.8	147.1	286.0	284.8
Costs and expenses:
Research and development expense	25.6	27.1	53.1	52.7
Sales and marketing expense	71.9	72.8	141.1	142.2
General and administrative expense	66.8	72.1	133.3	142.7
Goodwill and long-lived asset impairment charges	316.7	11.6	316.7	11.6
Total operating expenses	481.0	183.6	644.2	349.2
Operating loss	(329.2)	(36.5)	(358.2)	(64.4)
Other income (expense):
Interest income	0.2	0.4	0.5	1.0
Interest expense	(1.5)	(0.8)	(2.3)	(1.3)
Other	(0.1)	(0.3)	—	1.6
Total other income (expense), net	(1.4)	(0.7)	(1.8)	1.3
Loss before income tax	(330.6)	(37.2)	(360.0)	(63.1)
Income tax benefit	(0.1)	(0.5)	(29.4)	(0.4)
Net loss	$(330.5)	$(36.7)	$(330.6)	$(62.7)
Net loss per share:
Basic and Diluted	$(3.57)	$(0.41)	$(3.59)	$(0.69)
Weighted average shares outstanding:
Basic and Diluted	92.5	90.6	92.0	90.3

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.